The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 10, Pages 2792-2799
Publisher
Wiley
Online
2016-09-29
DOI
10.1002/cam4.878
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
- (2015) J. Zaragoza et al. BRITISH JOURNAL OF DERMATOLOGY
- Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
- (2015) S. Valpione et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma
- (2014) B. Schilling et al. ANNALS OF ONCOLOGY
- Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) A. J. Templeton et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system?
- (2013) Kostandinos Sideras et al. TRANSPLANT INTERNATIONAL
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
- (2009) S Mallett et al. BRITISH JOURNAL OF CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now